Fertility and Sterility
Volume 93, Issue 4 , Pages 1220-1226 , 1 March 2010

Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome

  • Athina Markou, M.D.

      Affiliations

    • Department of Endocrinology & Diabetes Center, National University of Athens, Mikras Asias, Athens, Greece
    • Corresponding Author InformationReprint requests: Athina Markou, M.D., Department of Endocrinology & Diabetes Center, General Hospital of Athens “G. Gennimatas,” Mesogeion 154, 11527 Athens, Greece (FAX: 30-210-7779146).
    • ,
  • Ioannis I. Androulakis, M.D.

      Affiliations

    • Department of Endocrinology & Diabetes Center, National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • Christos Mourmouris, M.D.

      Affiliations

    • Department of Radiology, General Hospital of Athens “G. Gennimatas,” National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • Ageliki Tsikkini, M.D.

      Affiliations

    • Department of Radiology, General Hospital of Athens “G. Gennimatas,” National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • Christianna Samara, M.D.

      Affiliations

    • Department of Radiology, General Hospital of Athens “G. Gennimatas,” National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • Stavros Sougioultzis, Ph.D.

      Affiliations

    • Department of Pathophysiology, National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • George Piaditis, Ph.D.

      Affiliations

    • Department of Endocrinology & Diabetes Center, National University of Athens, Mikras Asias, Athens, Greece
    • ,
  • Gregory Kaltsas, Ph.D.

      Affiliations

    • Department of Pathophysiology, National University of Athens, Mikras Asias, Athens, Greece

Received 5 September 2008 ,Revised 4 December 2008 ,Accepted 5 December 2008.

References 

  1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245
  3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236
  4. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–1460
  5. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257–1266
  6. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  7. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–1174
  8. Ketel IJ, Stehouwer CD, Serne EH, Korsen TJ, Hompes PG, Smulders YM, et al. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008;93:3365–3372
  9. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:2942–2945
  10. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–379
  11. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367–372
  12. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753–4761
  13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231
  14. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol. 2005;42(Suppl):S2–12
  15. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–1719
  16. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–2047
  17. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750
  18. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis. 2001;21:71–80
  19. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47:412–417
  20. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril. 2005;83:494–497
  21. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5:496–501
  22. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1741–1747
  23. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–443
  24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470
  25. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999;72:915–925
  26. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–514
  27. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998;171:659–664
  28. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85:4426–4433
  29. Suzuki A, Angulo P, Lymp J, St SJ, Muto A, Okada T, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64–71
  30. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa. Japan. Jpn J Med. 1988;27:142–149
  31. Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006;40:633–635
  32. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1139–1142
  33. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38
  34. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541–3546
  35. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol. 2003;15:539–543
  36. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134:1369–1375

 AM. has nothing to disclose. I.I.A. has nothing to disclose. C.M. has nothing to disclose. A.T. has nothing to disclose. C.S. has nothing to disclose. S.S. has nothing to disclose. G.P. has nothing to disclose. G.K. has nothing to disclose.

PII: S0015-0282(08)04645-1

doi: 10.1016/j.fertnstert.2008.12.008

Fertility and Sterility
Volume 93, Issue 4 , Pages 1220-1226 , 1 March 2010

Article Tools